UBS initiated coverage on Telix Pharmaceuticals with a new price target
$TLX
Biotechnology: Pharmaceutical Preparations
Health Care
UBS initiated coverage of Telix Pharmaceuticals with a rating of Buy and set a new price target of $21.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2025 | $22.00 | Outperform | Wedbush |
| 11/15/2024 | $21.00 | Buy | UBS |